Syncell
Assembly Line
Syncell Announces $15 Million Series A Funding to Accelerate the Global Commercial Growth of Its Protein Purification and Spatial Proteomics Technology
Syncell, a leader in next-generation subcellular protein purification and spatial proteomics analysis, today announced the close of a $15 million Series A funding round, bringing its total raised to $30 million. The investment will be used to expand and accelerate the global commercialization and commercial support for the company’s groundbreaking Microscoop platform. The round was led by Taiwania Capital, with participation from new and existing investors.
The pioneering Microscoop platform enables high-precision, unbiased, spatial proteomic discovery in subcellular tissues or cells, and has the ability to accurately discover new protein components from predetermined regions of interest. The technology also enables spatial protein purification for proteomic discovery, helping researchers identify cell subtypes and states, novel protein drug targets at disease-associated locations, biomarkers for disease, and mechanisms of biological pathways. The technology can power research focused on oncology, neurodegenerative diseases, infectious diseases, metabolic diseases, and developmental biology, as well as a range of drug discovery applications. Syncell recently won a Biotech Breakthrough Award with the Microscoop platform named “Proteomics Solution of the Year” for 2024.